Page last updated: 2024-11-07

pyrrolidin-3-yl-methanesulfonic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID125605
SCHEMBL ID20754591
MeSH IDM0127374

Synonyms (11)

Synonym
pmsa
pyrrolidin-3-ylmethanesulfonamide
95596-30-8
3-pyrrolidinemethanesulfonamide, 1,2,3,6-tetrahydro-, (+-)-
pyrrolidin-3-yl-methanesulfonic acid
1-(pyrrolidin-3-yl)methanesulfonamide
DTXSID30914924
JFINOWIINSTUNY-UHFFFAOYSA-N
SCHEMBL20754591
EN300-702738
(pyrrolidin-3-yl)methanesulfonamide

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" We report that, at high concentrations (300 microM-30 mM), a folic acid hexaglutamate analog is dose-dependently toxic to dissociated rat cortical cultures and that this toxicity is reversed by 2-PMPA, a potent and selective NAALADase inhibitor."( Toxicity induced by a polyglutamated folate analog is attenuated by NAALADase inhibition.
Olkowski, JL; Slusher, BS; Thomas, AG; Vornov, JJ, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (12.50)18.7374
1990's1 (12.50)18.2507
2000's0 (0.00)29.6817
2010's1 (12.50)24.3611
2020's5 (62.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.62 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (11.11%)6.00%
Case Studies3 (33.33%)4.05%
Observational0 (0.00%)0.25%
Other5 (55.56%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]